On Tuesday shares of Advaxis, Inc. (NASDAQ:ADXS) closed at $15.39. On 6 April, Advaxis, Inc. (NASDAQ:ADXS) announced that it is entering into a clinical trial collaboration agreement with the Radiation Therapy Oncology Group (RTOG) Foundation to evaluate the safety and efficacy of Advaxis’s lead cancer immunotherapy, ADXS-HPV (ADXS11-001), in a pivotal Phase 2/3 anal cancer…